Skip to main content
Top
Published in: Drugs & Aging 10/2014

01-10-2014 | Original Research Article

Adverse Drug Reactions in Elderly Subjects Hospitalized in a Specialized Dementia Management Unit

Authors: Lukshe Kanagaratnam, Rachid Mahmoudi, Jean-Luc Novella, Damien Jolly, Moustapha Dramé, Thierry Trenque

Published in: Drugs & Aging | Issue 10/2014

Login to get access

Abstract

Introduction

Drug prescriptions represent an actionable item in the prevention of adverse drug reactions (ADRs). The aims of this study were to identify risk factors for the occurrence of ADRs, and to describe symptoms and drug interactions.

Methods

This was a longitudinal study over a period of 19 months in an acute geriatric ward specializing in the management of dementia. Independent risk factors for ADRs were identified by logistic regression. Drug interactions were also recorded.

Results

In total, 293 patients were included (age 82 ± 8 years). The prevalence of ADRs was 24 %. Patients were taking 8 ± 3 drugs per day; 72 (24.6 %) were taking more than three psychotropics. The main therapeutic classes prescribed were anxiolytics and hypnotics (57.7 %), antidementia drugs (54.6 %), antidepressants (54.3 %), antithrombotics (54.0 %), angiotensin-converting enzyme inhibitors [ACEIs] or angiotensin II receptor blockers [ARBs] (37.5 %). The risk of ADRs was significantly higher in patients taking neuroleptics (odds ratio [OR] 2.04; 95 % confidence interval [CI] 1.06–3.92), ACEIs/ARBs (OR 2.07; 95 % CI 1.13–3.77) and antidementia drugs (OR 1.84; 95 % CI 1.01–3.36). The risk of serious ADRs was significantly higher in patients taking ACEIs/ARBs (OR 2.95; 95 % CI 1.40–6.21), type I, III or IV antiarrhythmics (OR 2.71; 95 % CI 1.07–6.88) or neuroleptics (OR 2.42; 95 % CI 1.09–5.40). Drug interactions were involved in 26.3 % (n = 21) of ADRs; the combination of an ADR plus a drug interaction was associated with increased severity (p = 0.02).

Conclusion

Caution is needed when prescribing ACEIs/ARBs, neuroleptics, antidementia drugs, or certain types of antiarrhythmics in patients suffering from dementia. Psychotropics should be avoided because of the associated risk of ADRs and drug interactions.
Literature
2.
go back to reference Ganjavi H, Herrmann N, Rochon PA, et al. Adverse drug events in cognitively impaired elderly patients. Dement Geriatr Cogn Disord. 2007;23(6):395–400.PubMedCrossRef Ganjavi H, Herrmann N, Rochon PA, et al. Adverse drug events in cognitively impaired elderly patients. Dement Geriatr Cogn Disord. 2007;23(6):395–400.PubMedCrossRef
3.
go back to reference Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288(12):1475–83.PubMedCrossRef Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288(12):1475–83.PubMedCrossRef
4.
go back to reference Lyketsos CG, Steinberg M, Tschanz JT, et al. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000;157(5):708–14.PubMedCrossRef Lyketsos CG, Steinberg M, Tschanz JT, et al. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000;157(5):708–14.PubMedCrossRef
5.
go back to reference Okura T, Plassman BL, Steffens DC, et al. Neuropsychiatric symptoms and the risk of institutionalization and death: the Aging, Demographics, and Memory Study. J Am Geriatr Soc. 2011;59(3):473–81.PubMedCrossRefPubMedCentral Okura T, Plassman BL, Steffens DC, et al. Neuropsychiatric symptoms and the risk of institutionalization and death: the Aging, Demographics, and Memory Study. J Am Geriatr Soc. 2011;59(3):473–81.PubMedCrossRefPubMedCentral
6.
go back to reference Masand PS. Side effects of antipsychotics in the elderly. J Clin Psychiatry. 2000;61(Suppl 8):43–9 (discussion 50–51).PubMed Masand PS. Side effects of antipsychotics in the elderly. J Clin Psychiatry. 2000;61(Suppl 8):43–9 (discussion 50–51).PubMed
8.
go back to reference Mahmoudi R, Dramé M, Morrone I, et al. Une unité de soins aigus pour les patients atteints de la maladie d’Alzheimer et syndromes apparentés: l’expérience rémoise. Neurol Psychiatr Gériatr. 2012;12(71):230–6.CrossRef Mahmoudi R, Dramé M, Morrone I, et al. Une unité de soins aigus pour les patients atteints de la maladie d’Alzheimer et syndromes apparentés: l’expérience rémoise. Neurol Psychiatr Gériatr. 2012;12(71):230–6.CrossRef
9.
go back to reference American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994. p. 143–7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994. p. 143–7.
10.
go back to reference WHO Collaborating Centre for International Drug Monitoring (UMC). Safety monitoring of medicinal products: guidelines for setting up and running a pharmacovigilance centre. London: EQUUS; 2000. WHO Collaborating Centre for International Drug Monitoring (UMC). Safety monitoring of medicinal products: guidelines for setting up and running a pharmacovigilance centre. London: EQUUS; 2000.
12.
go back to reference Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.PubMedCrossRef Folstein MF, Folstein SE, McHugh PR.  Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.PubMedCrossRef
13.
go back to reference Cockcroft DW, Gault H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.PubMedCrossRef Cockcroft DW, Gault H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.PubMedCrossRef
14.
go back to reference Gnjidic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012;65(9):989–95.PubMedCrossRef Gnjidic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012;65(9):989–95.PubMedCrossRef
16.
go back to reference Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. New York: Wiley; 2000. Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. New York: Wiley; 2000.
17.
go back to reference Caamaño F, Pedone C, Zuccalà G, et al. Socio-demographic factors related to the prevalence of adverse drug reaction at hospital admission in an elderly population. Arch Gerontol Geriatr. 2005;40(1):45–52.PubMedCrossRef Caamaño F, Pedone C, Zuccalà G, et al. Socio-demographic factors related to the prevalence of adverse drug reaction at hospital admission in an elderly population. Arch Gerontol Geriatr. 2005;40(1):45–52.PubMedCrossRef
18.
go back to reference Passarelli MCG, Jacob-Filho W, Figueras A. Adverse drug reactions in an elderly hospitalised population: inappropriate prescription is a leading cause. Drugs Aging. 2005;22(9):767–77.PubMedCrossRef Passarelli MCG, Jacob-Filho W, Figueras A. Adverse drug reactions in an elderly hospitalised population: inappropriate prescription is a leading cause. Drugs Aging. 2005;22(9):767–77.PubMedCrossRef
19.
go back to reference Laroche ML, Perault-Pochat MC, Ingrand I, et al. French Centres of Pharmacovigilance Network. Adverse drug reactions in patients with Alzheimer’s disease and related dementia in France: a national multicentre cross-sectional study. Pharmacoepidemiol Drug Saf. 2013;22(9):952–60.PubMed Laroche ML, Perault-Pochat MC, Ingrand I, et al. French Centres of Pharmacovigilance Network. Adverse drug reactions in patients with Alzheimer’s disease and related dementia in France: a national multicentre cross-sectional study. Pharmacoepidemiol Drug Saf. 2013;22(9):952–60.PubMed
20.
go back to reference Field TS, Gurwitz JH, Avorn J, et al. Risk factors for adverse drug events among nursing home residents. Arch Intern Med. 2001;161(13):1629–34.PubMedCrossRef Field TS, Gurwitz JH, Avorn J, et al. Risk factors for adverse drug events among nursing home residents. Arch Intern Med. 2001;161(13):1629–34.PubMedCrossRef
21.
go back to reference Onder G, Pedone C, Landi F, et al. Adverse drug reactions as cause of hospital admissions: results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA). J Am Geriatr Soc. 2002;50(12):1962–8.PubMedCrossRef Onder G, Pedone C, Landi F, et al. Adverse drug reactions as cause of hospital admissions: results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA). J Am Geriatr Soc. 2002;50(12):1962–8.PubMedCrossRef
22.
go back to reference Rountree SD, Atri A, Lopez OL, et al. Effectiveness of antidementia drugs in delaying Alzheimer’s disease progression. Alzheimers Dement. 2013;9(3):338–45.PubMedCrossRef Rountree SD, Atri A, Lopez OL, et al. Effectiveness of antidementia drugs in delaying Alzheimer’s disease progression. Alzheimers Dement. 2013;9(3):338–45.PubMedCrossRef
23.
go back to reference Atri A. Effective pharmacological management of Alzheimer’s disease. Am J Manag Care. 2011;17(Suppl 13):S346–55.PubMed Atri A. Effective pharmacological management of Alzheimer’s disease. Am J Manag Care. 2011;17(Suppl 13):S346–55.PubMed
24.
go back to reference Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289(9):1107–16.PubMedCrossRef Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289(9):1107–16.PubMedCrossRef
25.
go back to reference Prudent M, Dramé M, Jolly D, et al. Potentially inappropriate use of psychotropic medications in hospitalized elderly patients in France: cross-sectional analysis of the prospective, multicentre SAFEs cohort. Drugs Aging. 2008;25(11):933–46.PubMedCrossRef Prudent M, Dramé M, Jolly D, et al. Potentially inappropriate use of psychotropic medications in hospitalized elderly patients in France: cross-sectional analysis of the prospective, multicentre SAFEs cohort. Drugs Aging. 2008;25(11):933–46.PubMedCrossRef
26.
go back to reference Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry. 2001;62(Suppl 21):11–4.PubMed Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry. 2001;62(Suppl 21):11–4.PubMed
27.
go back to reference Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev. 2006;(1):CD003476. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev. 2006;(1):CD003476.
28.
go back to reference Laroche M-L, Charmes J-P, Merle L. Potentially inappropriate medications in the elderly: a French consensus panel list. Eur J Clin Pharmacol. 2007;63(8):725–31.PubMedCrossRef Laroche M-L, Charmes J-P, Merle L. Potentially inappropriate medications in the elderly: a French consensus panel list. Eur J Clin Pharmacol. 2007;63(8):725–31.PubMedCrossRef
29.
go back to reference Ballard C, Lana MM, Theodoulou M, et al. Investigators DART AD. A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PLoS Med. 2008;5(4):e76.PubMedCrossRefPubMedCentral Ballard C, Lana MM, Theodoulou M, et al. Investigators DART AD. A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PLoS Med. 2008;5(4):e76.PubMedCrossRefPubMedCentral
30.
go back to reference Marcum ZA, Fried LF. Aging and antihypertensive medication-related complications in the chronic kidney disease patient. Curr Opin Nephrol Hypertens. 2011;20(5):449–56.PubMedCrossRefPubMedCentral Marcum ZA, Fried LF. Aging and antihypertensive medication-related complications in the chronic kidney disease patient. Curr Opin Nephrol Hypertens. 2011;20(5):449–56.PubMedCrossRefPubMedCentral
31.
go back to reference Tipping B, Kalula S, Badri M. The burden and risk factors for adverse drug events in older patients: a prospective cross-sectional study. S Afr Med J. 2006;96(12):1255–9.PubMed Tipping B, Kalula S, Badri M. The burden and risk factors for adverse drug events in older patients: a prospective cross-sectional study. S Afr Med J. 2006;96(12):1255–9.PubMed
32.
go back to reference Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5(4):345–51.PubMedCrossRef Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5(4):345–51.PubMedCrossRef
34.
go back to reference Nguyen JK, Fouts MM, Kotabe SE, et al. Polypharmacy as a risk factor for adverse drug reactions in geriatric nursing home residents. Am J Geriatr Pharmacother. 2006;4(1):36–41.PubMedCrossRef Nguyen JK, Fouts MM, Kotabe SE, et al. Polypharmacy as a risk factor for adverse drug reactions in geriatric nursing home residents. Am J Geriatr Pharmacother. 2006;4(1):36–41.PubMedCrossRef
35.
go back to reference Onder G, Petrovic M, Tangiisuran B, et al. Development and validation of a score to assess risk of adverse drug reactions among in-hospital patients 65 years or older: the GerontoNet ADR risk score. Arch Intern Med. 2010;170(13):1142–8.PubMedCrossRef Onder G, Petrovic M, Tangiisuran B, et al. Development and validation of a score to assess risk of adverse drug reactions among in-hospital patients 65 years or older: the GerontoNet ADR risk score. Arch Intern Med. 2010;170(13):1142–8.PubMedCrossRef
36.
go back to reference Hoffmann W, van den Berg N, Thyrian JR, et al. Frequency and determinants of potential drug–drug interactions in an elderly population receiving regular home visits by GPs: results of the home medication review in the AGnES-studies. Pharmacoepidemiol Drug Saf. 2011;20(12):1311–8.PubMedCrossRef Hoffmann W, van den Berg N, Thyrian JR, et al. Frequency and determinants of potential drug–drug interactions in an elderly population receiving regular home visits by GPs: results of the home medication review in the AGnES-studies. Pharmacoepidemiol Drug Saf. 2011;20(12):1311–8.PubMedCrossRef
37.
go back to reference Becker ML, Kallewaard M, Caspers PWJ, et al. Hospitalisations and emergency department visits due to drug–drug interactions: a literature review. Pharmacoepidemiol Drug Saf. 2007;16(6):641–51.PubMedCrossRef Becker ML, Kallewaard M, Caspers PWJ, et al. Hospitalisations and emergency department visits due to drug–drug interactions: a literature review. Pharmacoepidemiol Drug Saf. 2007;16(6):641–51.PubMedCrossRef
Metadata
Title
Adverse Drug Reactions in Elderly Subjects Hospitalized in a Specialized Dementia Management Unit
Authors
Lukshe Kanagaratnam
Rachid Mahmoudi
Jean-Luc Novella
Damien Jolly
Moustapha Dramé
Thierry Trenque
Publication date
01-10-2014
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 10/2014
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-014-0206-0

Other articles of this Issue 10/2014

Drugs & Aging 10/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.